Impact of SSKI Pre-Treatment on Blood Loss in Thyroidectomy for Graves Disease
|ClinicalTrials.gov Identifier: NCT00946296|
Recruitment Status : Completed
First Posted : July 24, 2009
Results First Posted : December 15, 2015
Last Update Posted : December 15, 2015
|Condition or disease||Intervention/treatment||Phase|
|Graves Disease Hyperthyroidism||Drug: Potassium Iodide||Phase 4|
Historically Potassium Iodide was given to patients for 1 week prior to thyroidectomy. This common practice was used to decrease thyroid function and prevent thyroid storm during the thyroidectomy. However, in modern practice, nearly all patients presenting for surgical management have been made euthyroid through the use of medications such as propylthiouracil. Despite this potassium iodine continues to be administered with the presumption that it decreases the friability of the gland making surgery easier, with less blood loss.
The outcomes to be measured in this surgery are operative time, operative complications and blood loss.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||36 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Impact of SSKI Pre-Treatment on Blood Loss in Thyroidectomy for Graves Disease|
|Study Start Date :||April 2005|
|Primary Completion Date :||April 2013|
|Study Completion Date :||April 2013|
Active Comparator: Potassium Iodide
8 drops of Potassium Iodide in a glass of water, by mouth, daily for 7 days prior to operation.
Drug: Potassium Iodide
8 drops of Potassium Iodide in a glass of water taken daily for 7 days prior to thyroidectomy. This is the current standard of care.
Other Name: SSKI
No Intervention: No Treatment
The experimental group receives no treatment.
- Blood Loss During Surgery [ Time Frame: up to 162 minutes ]Blood loss in milliliters during surgery.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00946296
|United States, Massachusetts|
|UMASS Memorial Health Care|
|Worcester, Massachusetts, United States, 01655|